Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases is a phase 3, randomised interventional study registered as NCT04687631 by Fudan University, with a registry enrolment figure of 508 participants, started 2021-01-14 and due to reach its primary completion in 2025-03-31. Interventions recorded: mFOLFOXIRI plus Cetuximab; mFOLFOXIRI Plus Bevacizumab. Conditions listed: Colorectal Cancer; Liver Metastases. Primary outcome: Conversion resection rate of liver metastases. Colorectal eligibility wording from the registry: "The primary tumor was confirmed by histology as colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.